TY - JOUR T1 - Oxaliplatin-based Chemotherapy in Patients Aged 75 Years or Older with Metastatic Colorectal Cancer JF - Anticancer Research JO - Anticancer Res SP - 4627 LP - 4630 VL - 33 IS - 10 AU - MINORU FUKUCHI AU - KEIICHIRO ISHIBASHI AU - YUSUKE TAJIMA AU - NORIMICHI OKADA AU - MASARU YOKOYAMA AU - NORIYASU CHIKA AU - SATOSHI HATANO AU - TAKEAKI MATSUZAWA AU - KENSUKE KUMAMOTO AU - YOUICHI KUMAGAI AU - HIROYUKI BABA AU - ERITO MOCHIKI AU - HIDEYUKI ISHIDA Y1 - 2013/10/01 UR - http://ar.iiarjournals.org/content/33/10/4627.abstract N2 - Aim: To evaluate the tolerability and efficacy of oxaliplatin-based chemotherapy (OBC) in patients ≥75 years old with metastatic colorectal cancer (CRC). Patients and Methods: We reviewed the medical records of 126 patients with unresectable stage IV CRC in terms of OBC administered as first-line chemotherapy whenever feasible. Results: Use of first-line OBC was significantly less frequent in patients ≥75 years old (n=18) than in patients <75 years old (n=108) (46% vs. 81% p<0.01). When analysis was restricted to patients receiving OBC, the two age groups did not differ significantly in terms of response rate (44% vs. 36%, p=0.54), progression-free survival (18.7 months vs. 13.0 months, p=0.44), overall survival (25.4 months vs. 17.5 months, p=0.53), and frequency of grade 3-4 toxicity (72% vs. 58%, p=0.26). Conclusion: In selected patients aged 75 years or greater, the clinical outcomes of OBC seem equivalent to those of younger patients. ER -